ATE533514T1 - Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern - Google Patents
Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpernInfo
- Publication number
- ATE533514T1 ATE533514T1 AT04806061T AT04806061T ATE533514T1 AT E533514 T1 ATE533514 T1 AT E533514T1 AT 04806061 T AT04806061 T AT 04806061T AT 04806061 T AT04806061 T AT 04806061T AT E533514 T1 ATE533514 T1 AT E533514T1
- Authority
- AT
- Austria
- Prior art keywords
- polyethylene glycol
- antibodies
- branched polyethylene
- polymer residue
- linking polymer
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002062 molecular scaffold Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyethers (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329825.4A GB0329825D0 (en) | 2003-12-23 | 2003-12-23 | Biological products |
| PCT/GB2004/005246 WO2005061005A2 (en) | 2003-12-23 | 2004-12-14 | Branched polyethylene glycol for linking polymer residues to antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533514T1 true ATE533514T1 (de) | 2011-12-15 |
Family
ID=30776372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04806061T ATE533514T1 (de) | 2003-12-23 | 2004-12-14 | Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7736635B2 (de) |
| EP (1) | EP1699491B1 (de) |
| JP (1) | JP4833857B2 (de) |
| AT (1) | ATE533514T1 (de) |
| AU (1) | AU2004305291B2 (de) |
| CA (1) | CA2545805A1 (de) |
| ES (1) | ES2374201T3 (de) |
| GB (1) | GB0329825D0 (de) |
| WO (1) | WO2005061005A2 (de) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
| WO2007031734A1 (en) | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
| BRPI0809042B1 (pt) | 2007-03-22 | 2021-08-31 | Biogen Ma Inc. | Proteína de ligação a cd154 isolada, seu uso, e composição |
| AU2008334942A1 (en) * | 2007-12-13 | 2009-06-18 | Aduro Biotech | Ligand conjugated thermotherapy susceptors and methods for preparing same |
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| CH700543A2 (de) * | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
| EP2512450B1 (de) | 2009-12-15 | 2018-02-07 | Ascendis Pharma Endocrinology Division A/S | Transient an polymerträger gekoppelte trockene wachstumshormonzusammensetzungen |
| US8816099B2 (en) | 2010-03-31 | 2014-08-26 | Nof Corporation | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof |
| JP5945896B2 (ja) | 2011-09-30 | 2016-07-05 | 日油株式会社 | 分岐型ヘテロ多官能性ポリオキシアルキレン化合物、及びその中間体 |
| EP3553089A1 (de) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multispezifische monoklonale antikörper |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016019300A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| EP3180359A1 (de) | 2014-08-14 | 2017-06-21 | Novartis AG | Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor |
| EP3712171A1 (de) | 2014-08-19 | 2020-09-23 | Novartis AG | Behandlung von krebs mit einem chimären cd123-antigenrezeptor |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| KR102608645B1 (ko) | 2014-11-18 | 2023-12-01 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| EP4732848A3 (de) | 2014-11-21 | 2026-07-29 | Ascendis Pharma Endocrinology Division A/S | Langwirkende wachstumshormondosierformen |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| JP7573262B2 (ja) * | 2015-07-12 | 2024-10-25 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 細胞結合分子の共役のための架橋連結体 |
| EP3328418A1 (de) | 2015-07-29 | 2018-06-06 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| CN108697794A (zh) | 2015-12-17 | 2018-10-23 | 诺华股份有限公司 | C-met抑制剂和抗pd-1抗体分子的组合及其用途 |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| EP3851457A1 (de) | 2016-01-21 | 2021-07-21 | Novartis AG | Gegen cll-1 gerichtete multispezifische moleküle |
| SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3432924A1 (de) | 2016-03-23 | 2019-01-30 | Novartis AG | Zellsekretierte minikörper und verwendungen davon |
| US20230071283A1 (en) | 2016-04-15 | 2023-03-09 | Aimee S. Payne | Compositions and methods for selective protein expression |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| EP3484455A2 (de) | 2016-07-15 | 2019-05-22 | Novartis AG | Behandlung und prävention von zytokin-freisetzungssyndrom unter verwendung eines chimären antigenrezeptors in kombination mit einem kinasehemmer |
| KR20230100748A (ko) | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| SG11201900885VA (en) | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| JP2020105072A (ja) * | 2017-03-24 | 2020-07-09 | 協和キリン株式会社 | ポリエチレングリコール誘導体 |
| EP3615068A1 (de) | 2017-04-28 | 2020-03-04 | Novartis AG | Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor |
| EP3615055A1 (de) | 2017-04-28 | 2020-03-04 | Novartis AG | Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| CN111050791A (zh) | 2017-06-27 | 2020-04-21 | 诺华股份有限公司 | 用于抗tim-3抗体的给药方案及其用途 |
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| EP3713961A2 (de) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| EP3765517A1 (de) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | An calreticulin bindende multifunktionsmoleküle und ihre verwendungen |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| CN112384534A (zh) | 2018-05-21 | 2021-02-19 | 指南针制药有限责任公司 | 用于增强nk细胞对靶细胞的杀死的组合物和方法 |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| CA3104295A1 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| JP2021531306A (ja) | 2018-07-25 | 2021-11-18 | アドバンスド アクセラレーター アプリケーションズ エスエー | 神経内分泌腫瘍の処置の方法 |
| JP7497351B2 (ja) | 2018-11-13 | 2024-06-10 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20210386763A1 (en) | 2018-12-20 | 2021-12-16 | Novartis Ag | Pharmaceutical combinations |
| EP3924054B1 (de) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| EP3927371A1 (de) | 2019-02-22 | 2021-12-29 | Novartis AG | Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren |
| JP7524206B2 (ja) | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス | 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 |
| PH12021552414A1 (en) | 2019-03-29 | 2022-07-25 | Atarga Llc | Anti fgf23 antibody |
| WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN115298322A (zh) | 2020-01-17 | 2022-11-04 | 贝克顿迪金森公司 | 用于单细胞分泌组学的方法和组合物 |
| EP4090335A1 (de) | 2020-01-17 | 2022-11-23 | Novartis AG | Kombination aus einem tim-3-inhibitor und einem hypomethylierungsmittel zur verwendung bei der behandlung von myelodysplastischem syndrom oder chronischer myelomonozytischer leukämie |
| IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
| EP4168007A1 (de) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosierschema mit 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivaten |
| CA3176556A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| EP4188549A1 (de) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
| KR20230107617A (ko) | 2020-11-13 | 2023-07-17 | 노파르티스 아게 | 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법 |
| EP4284510A1 (de) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CA3263767A1 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER |
| WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026036047A1 (en) | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| US20260167709A1 (en) | 2024-09-11 | 2026-06-18 | Novartis Ag | Antibodies targeting il-31 |
| WO2026102093A1 (en) | 2024-11-07 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026151679A1 (en) | 2025-01-07 | 2026-07-16 | Compass Therapeutics, Llc. | Multispecific binding constructs targeting pd-1 and vegf and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB315450A (en) | 1928-04-10 | 1929-07-10 | Hozumi Kita | Improvements in door controlling apparatus |
| GB315457A (en) | 1928-04-13 | 1929-07-15 | Reyrolle A & Co Ltd | Improvements in or relating to electric couplings |
| US1890060A (en) | 1928-09-22 | 1932-12-06 | Du Pont | Process of polymerizing vinyl derivatives |
| GB329825A (en) | 1929-05-14 | 1930-05-29 | Edward Victor Hammond | Improvements in jockey pulley apparatus |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| CA2323048C (en) * | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| DE10048417A1 (de) | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
| JP4602577B2 (ja) * | 2001-03-15 | 2010-12-22 | 積水メディカル株式会社 | 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬 |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| US20030211078A1 (en) * | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
| DE60315145T2 (de) * | 2002-03-13 | 2008-04-30 | Beijing Jiankai Technology Co., Ltd. | Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff |
| ATE444984T1 (de) * | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| KR100512483B1 (ko) * | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| GB0319588D0 (en) | 2003-08-20 | 2003-09-24 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| DE10329948B4 (de) | 2003-07-03 | 2005-05-25 | Koenig & Bauer Ag | Heftapparat mit einem wenigstens zwei Heftköpfe tragenden Heftzylinder |
| AU2003903500A0 (en) | 2003-07-08 | 2003-07-24 | Robinson, Samantha Renae | Display device for greeting cards |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
-
2003
- 2003-12-23 GB GBGB0329825.4A patent/GB0329825D0/en not_active Ceased
-
2004
- 2004-12-14 JP JP2006546297A patent/JP4833857B2/ja not_active Expired - Fee Related
- 2004-12-14 ES ES04806061T patent/ES2374201T3/es not_active Expired - Lifetime
- 2004-12-14 AT AT04806061T patent/ATE533514T1/de active
- 2004-12-14 AU AU2004305291A patent/AU2004305291B2/en not_active Ceased
- 2004-12-14 US US10/583,642 patent/US7736635B2/en not_active Expired - Fee Related
- 2004-12-14 WO PCT/GB2004/005246 patent/WO2005061005A2/en not_active Ceased
- 2004-12-14 CA CA002545805A patent/CA2545805A1/en not_active Abandoned
- 2004-12-14 EP EP04806061A patent/EP1699491B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007515463A (ja) | 2007-06-14 |
| WO2005061005A3 (en) | 2005-11-03 |
| AU2004305291A1 (en) | 2005-07-07 |
| AU2004305291B2 (en) | 2010-06-24 |
| CA2545805A1 (en) | 2005-07-07 |
| US7736635B2 (en) | 2010-06-15 |
| EP1699491A2 (de) | 2006-09-13 |
| GB0329825D0 (en) | 2004-01-28 |
| EP1699491B1 (de) | 2011-11-16 |
| ES2374201T3 (es) | 2012-02-14 |
| US20070128150A1 (en) | 2007-06-07 |
| WO2005061005A2 (en) | 2005-07-07 |
| JP4833857B2 (ja) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0329825D0 (en) | Biological products | |
| WO2021243122A3 (en) | Engineered coronavirus spike (s) protein and methods of use thereof | |
| NO20052089L (no) | Polymerkonjugater med redusert antigenisitet, fremgangsmater for fremstillling og anvendelse derav | |
| CY1108685T1 (el) | Συστημα απελευθερωσης φαρμακου που πηζει in-situ | |
| NO20072997L (no) | Posisjonsstyrt omdanning av FVIII | |
| CY1118120T1 (el) | Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων | |
| EA202191651A1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| DK1459065T3 (da) | Fremgangsmåde til målingen af styrken af glatirameracetat | |
| MX382756B (es) | Polimeros de tiol-eno degradables y metodos para hacer los mismos. | |
| BRPI0607988A2 (pt) | composto, composição farmacêutica, e método para induzir apoptose em uma célula | |
| BR0317296A (pt) | Método de tratamento de uma formação subterrânea | |
| DK1660528T3 (da) | Mutein af tåre-lipocalin | |
| ATE485331T1 (de) | Thiolselektive wasserlösliche polymerderivate | |
| CY1113684T1 (el) | Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη | |
| WO2004099231A3 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
| DK1144607T3 (da) | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
| GT200800154A (es) | N-sulfonilacion selectiva de alcoholes 2-amino trifluoroalquilo sustituidos | |
| AR067627A1 (es) | Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| DE602004016532D1 (de) | Verbindungen und kits zur herstellung von bildgebenden mitteln und bildgebungsverfahren | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| ATE498022T1 (de) | Universelle vervielfältigung von fragmentierter rns | |
| ATE461960T1 (de) | Verfahren zur herstellung von polymermaleimiden | |
| DE602004021501D1 (de) | Gegenüber ionisierender strahlung stabile polyarylestercarbonatzusammensetzungen | |
| YU90301A (sh) | Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane |